AI Engines For more Details: Perplexity Kagi Labs You
Protozoal Infections: Ornidazole is effective against protozoal infections such as:
Bacterial Infections: Ornidazole may also be used to treat certain bacterial infections, including:
Anaerobic Infections: Ornidazole is particularly effective against anaerobic bacteria, which thrive in the absence of oxygen. It is used to treat infections caused by anaerobic bacteria in various body systems, including the gastrointestinal tract, genitourinary tract, and respiratory tract.
Mechanism of Action: Ornidazole works by disrupting the DNA structure and function of susceptible organisms, leading to cell death and elimination of the infection.
Dosage and Administration: Ornidazole is typically administered orally in the form of tablets or suspension. The dosage and duration of treatment depend on the type and severity of the infection, as well as the patient's age, weight, and medical history. It is important to complete the full course of treatment as prescribed by a healthcare professional, even if symptoms improve before the medication is finished.
Adverse Effects: Common side effects of ornidazole may include nausea, vomiting, diarrhea, abdominal discomfort, headache, dizziness, and metallic taste in the mouth. Rare but serious adverse effects may include allergic reactions, peripheral neuropathy, and seizures. Patients should seek medical attention if they experience severe or persistent side effects while taking ornidazole.
Precautions: Ornidazole should be used with caution in patients with a history of central nervous system disorders, hepatic impairment, or blood dyscrasias. It should be avoided in pregnant women, breastfeeding mothers, and children, unless the potential benefits outweigh the risks.
Drug Interactions: Ornidazole may interact with certain medications, including warfarin and other anticoagulants, causing an increased risk of bleeding. It is important to inform a healthcare professional about all medications, supplements, and herbal products being taken before starting treatment with ornidazole.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| species | Phocaeicola coprocola | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.7 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.9 | 0.6 | 5.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.2 | 1.8 | 0.78 |
| Allergies | 7.8 | 4.1 | 0.9 |
| Allergy to milk products | 2.2 | 1.7 | 0.29 |
| Alopecia (Hair Loss) | 1.7 | 1.7 | |
| Alzheimer's disease | 7.4 | 7.8 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1 | 3.3 |
| Ankylosing spondylitis | 5 | 1.9 | 1.63 |
| Anorexia Nervosa | 1.9 | 3 | -0.58 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 5.7 | 2.6 | 1.19 |
| Atherosclerosis | 2.2 | 2.4 | -0.09 |
| Atrial fibrillation | 3.8 | 3.2 | 0.19 |
| Autism | 11.8 | 10.7 | 0.1 |
| Autoimmune Disease | 0.9 | 1 | -0.11 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.4 | 0.5 |
| Biofilm | 1.6 | 1.6 | |
| Bipolar Disorder | 2.5 | 1.7 | 0.47 |
| Brain Trauma | 0.6 | 1.5 | -1.5 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.9 | 1.9 | -1.11 |
| Carcinoma | 5.3 | 3.2 | 0.66 |
| Celiac Disease | 3 | 4.9 | -0.63 |
| Cerebral Palsy | 1.7 | 1.4 | 0.21 |
| Chronic Fatigue Syndrome | 5.8 | 7.4 | -0.28 |
| Chronic Kidney Disease | 5.1 | 3.4 | 0.5 |
| Chronic Lyme | 0.6 | 0.9 | -0.5 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 1.2 | 2 | -0.67 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 1 | 0.1 |
| Cognitive Function | 3.2 | 1.3 | 1.46 |
| Colorectal Cancer | 7.2 | 3 | 1.4 |
| Constipation | 2.7 | 0.7 | 2.86 |
| Coronary artery disease | 2.2 | 3.1 | -0.41 |
| COVID-19 | 11.3 | 13.9 | -0.23 |
| Crohn's Disease | 10.1 | 7.8 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.4 | -1 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.6 | 1.2 | 1.17 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 11.5 | 11.2 | 0.03 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 2.3 | 1 | 1.3 |
| Endometriosis | 3.3 | 2.1 | 0.57 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.7 | 2.9 | 0.28 |
| erectile dysfunction | 1.5 | 0.3 | 4 |
| Fibromyalgia | 3.7 | 2.5 | 0.48 |
| Functional constipation / chronic idiopathic constipation | 7 | 4.7 | 0.49 |
| gallstone disease (gsd) | 3.8 | 1.6 | 1.37 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.5 | 1.4 | 0.79 |
| Generalized anxiety disorder | 3.2 | 2.3 | 0.39 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 2.2 | 1 | 1.2 |
| Graves' disease | 2 | 3.4 | -0.7 |
| Gulf War Syndrome | 0.9 | 2.3 | -1.56 |
| Halitosis | 1.6 | 1.6 | |
| Hashimoto's thyroiditis | 4.5 | 2.4 | 0.88 |
| Heart Failure | 4.7 | 2.4 | 0.96 |
| hemorrhagic stroke | 2.4 | 2.4 | |
| Hidradenitis Suppurativa | 1.3 | 0.3 | 3.33 |
| High Histamine/low DAO | 1.4 | 0.6 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 1.9 | 2.3 | -0.21 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.6 | 5.8 | -0.04 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 4 | 0.3 | 12.33 |
| IgA nephropathy (IgAN) | 1.7 | 5.2 | -2.06 |
| Inflammatory Bowel Disease | 9.3 | 11.2 | -0.2 |
| Insomnia | 1.7 | 3.8 | -1.24 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.6 | 0.6 | 1.67 |
| Irritable Bowel Syndrome | 9.6 | 6.2 | 0.55 |
| ischemic stroke | 2.8 | 1.8 | 0.56 |
| Liver Cirrhosis | 8.3 | 5.3 | 0.57 |
| Long COVID | 8.2 | 9.4 | -0.15 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1.6 | -0.33 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.9 | 0.33 |
| ME/CFS with IBS | 0.8 | 2.5 | -2.13 |
| ME/CFS without IBS | 1.7 | 2.5 | -0.47 |
| Menopause | 1 | 1.1 | -0.1 |
| Metabolic Syndrome | 9.3 | 9.2 | 0.01 |
| Mood Disorders | 12.9 | 9.1 | 0.42 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 8.9 | 6.8 | 0.31 |
| Multiple system atrophy (MSA) | 1.7 | 1 | 0.7 |
| myasthenia gravis | 0.6 | 0.7 | -0.17 |
| neuropathic pain | 0.3 | 3.7 | -11.33 |
| Neuropathy (all types) | 0.9 | 2.2 | -1.44 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.6 | 5.4 | 0.04 |
| NonCeliac Gluten Sensitivity | 2 | 0.7 | 1.86 |
| Obesity | 12.9 | 10.1 | 0.28 |
| obsessive-compulsive disorder | 5.7 | 5.2 | 0.1 |
| Osteoarthritis | 2.9 | 1.5 | 0.93 |
| Osteoporosis | 3.1 | 1.7 | 0.82 |
| pancreatic cancer | 0.9 | 0.9 | |
| Parkinson's Disease | 9.7 | 8 | 0.21 |
| Polycystic ovary syndrome | 7.8 | 3.8 | 1.05 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.2 | -0.33 |
| Primary sclerosing cholangitis | 2.2 | 3.2 | -0.45 |
| Psoriasis | 4.1 | 4.1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 10.2 | 5 | 1.04 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.7 | 3.7 | 1.08 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 2.9 | 2.5 | 0.16 |
| Sleep Apnea | 2.2 | 2 | 0.1 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.6 | 0.6 | 3.33 |
| Stress / posttraumatic stress disorder | 3.8 | 3.6 | 0.06 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.4 | 1.8 | -0.29 |
| Tourette syndrome | 1.1 | 0.4 | 1.75 |
| Type 1 Diabetes | 4.5 | 3.5 | 0.29 |
| Type 2 Diabetes | 10.2 | 7.9 | 0.29 |
| Ulcerative colitis | 6.9 | 9.2 | -0.33 |
| Unhealthy Ageing | 6.7 | 2.9 | 1.31 |
| Vitiligo | 2.3 | 2.3 | 0 |
